ONCO — Oncopeptides AB Cashflow Statement
0.000.00%
Last trade - 00:00
- SEK844.10m
- SEK807.36m
- SEK35.22m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -739 | -1,591 | -1,421 | -349 | -253 |
Depreciation | |||||
Non-Cash Items | -8.19 | 161 | -44.3 | 19.2 | 18.9 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 57 | 134 | -51.1 | -108 | -45 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -691 | -1,297 | -1,516 | -421 | -279 |
Capital Expenditures | -0.517 | -17.2 | -0.339 | -2.51 | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -2.11 | -2.95 | 0 | 0 | -0.116 |
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2.63 | -20.1 | -0.339 | -2.51 | -0.116 |
Financing Cash Flow Items | -33.2 | -76.2 | -56.6 | -28.1 | 109 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1,236 | 1,323 | 1,034 | 392 | 109 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 551 | -85.9 | -478 | -17.7 | -171 |